Status:
COMPLETED
Hypoxia-altitude Testing to Predict Altitude Related Adverse Health Effects in Chronic Obstructive Pulmonary Disease (COPD) Patients
Lead Sponsor:
University of Zurich
Collaborating Sponsors:
National Center of Cardiology and Internal Medicine, Kyrgyz Republic
Conditions:
Hypoxia Altitude Simulation Test
High Altitude
Eligibility:
All Genders
35-75 years
Brief Summary
The predictive value of the hypoxia altitude simulation test (HAST) or other baseline values to predict altitude-related adverse health effects (ARAHE) is not established. To address this gap, the mai...
Detailed Description
Altitude or air travel has become increasingly popular for recreational and professional reasons. Chronic obstructive pulmonary disease (COPD) affects up to 12% of adults worldwide and is associated w...
Eligibility Criteria
Inclusion
- Men and women, age 35-75 y, living at low altitude (\<800 m).
- COPD diagnosed according to the Global Initiative for Obstructive Lung Disease (GOLD) guidelines, FEV1 40-80% predicted, pulse oximetry ≥92%, PaCO2 \<6 kPa, breathing ambient air at 760 m.
Exclusion
- COPD exacerbation, very severe COPD with hypoxemia or hypercapnia at 760 m (see above).
- Other lung disease, relevant comorbidities (such as uncontrolled cardiovascular disease, i.e., unstable arterial hypertension, coronary artery disease; previous stroke; obesity (body mass index \>35 kg/m2); internal, neurologic, rheumatologic or psychiatric disease; current heavy smoking (\>20 cigarettes per day).
- Renal failure and/or allergy to sulfonamides.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2022
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT04915378
Start Date
June 1 2021
End Date
May 31 2022
Last Update
June 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Center of Cardiology and Internal Medicine
Bishkek, Kyrgyzstan, 720040